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H. Massin6Departments of 1Vascular Surgery, AZ St Blasius, Dendermonde, 2Cardiovascular and Thoracic Surgery,
Imelda Hospital, Bonheiden, 3Vascular Surgery, St Jozef Hospital, Sint-Truiden, 4Vascular Surgery, UZ Gent,
Gent, 5Center for Vascular Diseases, UZ Leuven, Leuven, and 6Vascular Surgery, St Joseph, Gilly, BelgiumBackground. The purpose of this study was to assess the safety and efficacy of translating into national practice
methodology for infrainguinal excimer laser-assisted angioplasty, for the treatment of critical limb ischemia in poor surgical
bypass candidates.
Methods. A prospective five centre Belgian registry enrolled 48 patients, who presented with 51 chronic critically ischemic
limbs (Rutherford category 4, 5 or 6) and were poor candidates for bypass surgery. Treatment included crossing the occlusion
or stenosis by conventional guidewire followed by excimer laser angioplasty with, or without, adjunctive balloon angioplasty
or stenting. A step-by-step technique was used in cases where the guidewire could not pass the occluded site. The primary
endpoint was limb salvage, at 6 months, of the treated limb.
Results. Initial treatment was successful in all 51 limbs. By 6 months there had been six deaths, six minor and four major
amputations and further intervention was required in four patients. Among survivors, limb salvage rate at 6 month was
38/42 (90.5%), with freedom from critical limb ischemia in 86%.
Conclusions. This Belgian study of eximer laser assisted angioplasty, in high-risk patients who were poor candidates for
surgical re-vascularisation, had a low incidence of surgical re-interventions and limb salvage rate in excess of 90%.Keywords: Critical limb ischemia; Excimer laser; Revascularisation; Limb salvage; Infrapopliteal.Introduction
Two decades after the clinical introduction of balloon
angioplasty (PTA) as a recanalization technique in the
femoropopliteal and infrageniculate arteries, a num-
ber of factors affecting the primary and long-term
success of the procedure have been identified.1–4 Short
lesion length, minimal vascular disease elsewhere
with good peripheral run-off, symptoms of claudica-
tion as opposed to limb-threatening ischemia, stenosis
rather than occlusion, and the absence of diabetes all
correlate with improved primary success and long-
term patency.5–17 For patients with critical limb
ischemia (CLI), treatment options remain limited to
medical management, bypass surgery or amputation.
Those too fragile or unwilling to undergo the
morbidity and mortality associated with bypassng author. Marc Bosiers, MD, Department of Vascular
Sint-Blasius, Kroonveldlaan 50, 9200 Dendermonde,
es: marc.bosiers@pandora.be, info@fmrp.be
0613+ 07 $35.00/0 q 2005 Elsevier Ltd. All rights resersurgery are left to live with their pain or lose a lower
limb.
Using PTA alone in the treatment of long below-the-
knee occlusions has resulted in disappointing patency
rates, although immediate clinical improvement has
beenachieved.2,5,6Withadvances in interventional tools,
e.g. the excimer laser andcoated/nitinol stents, andwith
the adoption of coronary interventional techniques in
peripheral arteries, there are new possibilities for
effectively treating total occlusions and diffuse disease
below the knee.18,19 Excimer lasing re-opens and
enlarges the lumen and smoothens the lumen wall,
enhancing the angiographic result of adjunctive PTA.20–
22 Results of recent clinical studies have associated these
effects of excimer lasing with clinical outcomes;22–24 this
raises the question of whether such promising results
can be sustained in routine clinical practice.LACI Belgium
Given the promising results of laser angioplasty in
critical limb ischemia (LACI),23,24 we studied theEur J Vasc Endovasc Surg 29, 613–619 (2005)
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Belgium. The purpose of this study was to provide
confirmatory evidence of the safety and efficacy of the
LACI treatment strategy as specifically practised in
Belgium.Materials
This study was a prospective consecutive multicentre
clinical registry at five sites in Belgium (Table 1).
Patients were eligible for study inclusion if there was
objective evidence of chronic critical limb ischemia
(rest pain or non-healing ulcerative lesions or
gangrene) with lesions in the superficial femoral,
popliteal and/or infrapopliteal arteries. Written
patient consent was required prior to patient enrol-
ment. Local ethics committee approval was received
prior to study initiation. This study was conducted in
accordance with the Declaration of Helsinki.
Between January 7, 2003 and June 6, 2003, 48
patients were enrolled. LACI Belgium included
patients with CLI (Rutherford Category 4–6) who
had at least one angiographically identifiable infra-
geniculate target artery and who were poor surgical
candidates. A poor surgical candidate was identified
when any one of the following criteria was met:
absence of venous autologous grafts; absence of or
poor distal vessels for graft anastomosis; high risk
surgical mortality evidence by ASA Physical Class 4 or
higher. Treatment consisted of excimer laser angio-
plastyCPTACoptional stent, with the primary end-
points being limb salvage, wound healing, straight-line
flow until the foot and total survival at 6 months.
Exclusion criteria were age below 18 years; preg-
nancy, or plan to become pregnant; participation in
another cardiovascular or peripheral vascular IDE
study; myocardial infarction (MI) in prior month;
disorder or allergies precluding use of radiographic
contrast; renal insufficiency severe enough toTable 1. Investigators LACI Belgium
Site name Investigator Leg Pt
Imelda Ziekenhuis,
Bonheiden
Dr Peeters 15 13
A.Z. Sint-Blasius,
Dendermonde
Dr Bosiers 14 13
U.Z. Gent, Gent Prof Vermassen 3 3
Hoˆpital Saint-Jozef,
Gilly
Dr Massin 1 1
U.Z. Leuven-
Gasthuisberg,
Leuven
Dr Maleux 10 10
Sint-Trudo Zieken-
huis, Sint-Truiden
Dr Van Elst 8 8
Total 51 48
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indication to treatment with anticoagulants; untreated
ipsilateral iliac stenosisO70%; inability or unwilling-
ness of the patient to comply with intended examin-
ations; lesions located in a graft; hemodynamically
significant arrhythmia or left ventricular ejection
fraction!20%; life expectancy less than 6 months;
necrosis necessitating major amputation; or unavail-
ability of required procedural or imaging equipment.
The primary endpoint of this study was limb
salvage (absence of major amputation, defined as an
amputation of the treated limb at or above the ankle) at
6 months, on a per-limb basis. The secondary end-
points were: ‘Peripheral vascular endpoint,’ defined as
major amputation or persistent CLI at 6 months (basis:
limb); death during the follow-up period (basis:
patient); incidence of minor amputation (basis: limb);
persistent CLI (basis: limb); visual assessment of the
healing process of ulcers (basis: ulcer); surgical bypass
in the leg (basis: limb); surgical bypass to a previously
unavailable site (basis: limb); reduction in degree of
planned lower extremity amputation (basis: limb);
angiographic procedural success rate (basis: limb)
with angiographic procedural success defined as 50%
or less residual stenosis on visual assessment of the
planned area of treatment after completion of treat-
ment, without serious adverse events and before the
arterial sheath was removed. Data management was
performed by Flanders Medical Research Program,
Hamme.Methods
Using standard intravascular techniques, a guidewire
crossed the entire occlusion and entered the distal
vessel beyond the target lesion. If free movement of the
wire tip within the distal vessel was not observed, the
wire was withdrawn and redirected. As an alternative
method of recanalization, laser ablation was used in a
step-by-step manner where the guidewire and then a
laser catheter are sequentially advanced and activated
in telescoping fashion until the occlusion was crossed.
This step-by-step technique was used in 16% of the
treated limbs.
After the wire crossed the target lesion, the lesion
was treated with excimer laser atherectomy, unless
satisfactory debulking had already been achieved
through use of the step-by-step approach. Laser
catheter sizes between 0.9 m and 2.5 mmwere allowed
(CLiRpath catheters, Spectranetics, Colorado Springs,
Colorado, USA). It was recommended that as much
tissue as possible was removed to achieve an optimal
laser channel (at least 30–50% of vessel diameter). To
LACI Belgium 615optimise the atherectomy, the laser catheter tip was
advanced at a speed of approximately 0.5–1 mm/s
while lasing and infusing saline through the guide
catheter. After the laser catheter crossed the occlusion
an angiogram was undertaken to assess the laser
channel. Additional passes were made to improve the
initial laser result at the discretion of the investigator.
Following laser use, PTA was delivered according
to local standards. If an unsatisfactory result or a flow-
limiting dissection ensued, stent implantation was
used to achieve a widely patent lumen. Treatment
typically advanced from the pelvic arteries to the
tibial/pedal arteries until ‘straight line flow’ through
at least one tibial artery was achieved from the groin to
the foot. Anticoagulation was administered according
to local standards, typically including aspirin, heparin,
clopidogrel, and occasional use of Gp IIb/IIIa
antagonists.Results
A total of 48 patients (32 men), with 51 critically
ischemic limbs and a mean age of 74.6 years (range
38–94) were enrolled. There was a high incidence ofTable 2. LACI Belgium patient and limb characteristics
History of coronary artery disease
(CAD)
29 57%
History of MI 12 24%
History of CABG 9 18%
History of PTCA 4 8%
Familial history of CAD 4 8%
Other 10 20%
History of stroke or CVA 14 27%
History of hypertension 38 75%
History of diabetes 24 47%
Diet controlled 2 4%
Oral hypoglycemics 7 14%
Insulin dependent 15 29%
History of hypercholesterolemia 25 49%
History of obesity 16 31%
Smoking past 12 24%
Smoking current 10 20%
History of CLI in treatment limb (NZ51)
History of CLI 48 94%
Rest pain 38 75%
Non-healing ulcerative wounds 24 47%
Gangrene 3 6%
Planned amputation 1 2%
Poor surgical candidacy (NZ51)
Absence of venous autologous graft 12 24%
Poor or no distal vessel 25 49%
High risk of surgical mortality (ASA
class 4 or higher)
30 59%
Any two reasons 11 22%
All three reasons 5 10%
Rutherford category (NZ51)
Category 4 25 49%
Category 5 21 41%
Category 6 5 10%co-morbidities (Table 2). The actual outer diameter of
laser catheters used and treated lesion locations are
given in Table 3.
An antegrade approach was used in 84% of the
patients to achieve good back-up support and align-
ment of the laser catheter. In 16% of the patients a
contra-lateral approach (crossover) was used, with
adequate back-up support at the iliac bifurcation to
ensure appropriate device control at the treatment site.
Additional balloon dilatation was required in 33%
of the patients to optimize the angiographic result; 6%
of the patients had direct stenting after laser angio-
plasty; 47% required adjunctive PTA in combination
with stent placement. In 14% of the patients excimer
laser atherectomy was performed as a stand-alone
procedure. All reported data and results were
obtained by one of the treatments listed above. The
study was not intended or powered to show statistical
differences between the used treatment and/or a
combination of the treatments (Table 4).
After 6 months, a limb salvage rate of 90.5% was
obtained (38 out of the 42 surviving patients at 6
month follow-up (Table 5). During the 6-month follow
period six patients died, five due to cardiac disease
and one due to general systemic deterioration. Minor
amputation, defined as an amputation of the distal or
the mid-foot, leaving the patient with an ambulatory
foot, was required in six patients throughout the
follow up period. Four patients needed a major
amputation, defined as amputation at or above the
ankle. Surgical intervention was needed in two
patients, and two patients received endovascular
re-intervention. Freedom from any of these adverse
events was observed in 76% of surviving patients at
the end of the 6-month follow up period.
Rutherford classification improved as demon-
strated in Graph 1. Of the 35 surviving legs with
6-month data, 30 (86%) were free of CLI.Table 3. Laser catheter size and lesion locations
Laser catheter size distribution
OD laser catheter tip Number of catheters
0.9 mm 6
1.4 mm 9
1.7 mm 5
2.0 mm 13
2.3 mm 15
2.6 mm 15
Mean laser pulses delivered
(no data in 12 patients)
3430 (900–11,100)
Average lasing time 134 (18–1200) s
Treated lesions
Femoro-popliteal 21 41%
Infra-popliteal 16 31%
Combined 14 27%
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Table 4. Adjunctive therapy used
Lasing 7 14%
Lasing and PTA 17 33%
Lasing and stenting 3 6%
Lasing, PTA and stenting 24 47%
Balloon information
Mean number of PTA
balloons used
1.24 63
Mean balloon diameter 4.06 (2–6)
Stent information
Mean number of stents
used
1.02 52
Mean stent diameter 5.60 (3–8)
Mean stent length 46.55 (40–100)
Graph 1. Evolution in Rutherford categorisation after 1, 3
and 6 months (NZ51). N.A., not available. No information
because the referred patients were lost to follow-up; N.D.,
not done. No information because no Rutherford evaluation
was done at this follow-up visit.
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The basic concept of laser atherectomy is to apply light
energy directly to the arterial plaque, thereby altering
the plaque in a beneficial manner, without damaging
the surrounding artery. Lasers suitable for intravas-
cular use produce an intense monochromatic light
beam that can be delivered through fiberoptic cath-
eters to a small area of tissue with great precision.
There are three parameters that define the laser/tissue
interaction: absorption depth, pulse width and aver-
age power. Absorption depth can be defined as how
deep the light propagates into the tissue. For precise
work, this penetration depth must be as small as
possible, to ensure that effects are localized to the point
where the beam is applied and is determined only by
the wavelength and the tissue. Each laser type emits a
characteristic wavelength that is determined by the
gain medium inside the laser. Selecting a particular
wavelength to use in vascular tissue is fairly straight-
forward, once the typical absorption spectrum of
tissue is plotted. In the near-infrared regions, between
2000 and 3000 nm, water is the dominant absorber; the
light penetration depth varies from about 1 to 0.1 mm
over this region. At the other end of the spectrum, in
the UVB region near 300 nm, the absorption depth is
shallow, owing to absorption by cellular macromol-
ecules. Another advantage of using UVB light lies inTable 5. Overall LACI Belgium results
Discharge
N 51
Death 0
Lost to follow-up 0
Major amputation 0
Limb salvage (patients with freedom of death, not
lost to follow-up)
51/51 (100%
Limb salvage by intend-to-treat analysis –
Minor amputation 0
Surgical repair 0
Endovascular repair 0
Freedom of any procedure 51/51 (100%
Eur J Vasc Endovasc Surg Vol 29, June 2005its ability to break molecular bonds directly, by a
photochemical process. Delicatemeasurements in tissue
indicate that about 2% of the UVB photons absorbed by
the proteins and lipids in cells actually breaks bonds,
which weakens or lyses cellular structures. This direct
lytic action is a unique feature of using ultraviolet light.
The secondparameter in light/tissue interaction ispulse
width. For all lasers,most of the light energyabsorbedby
the tissue is converted to heat almost instantly. The third
parameter of light/tissue interaction is average power.
Ideally, the absolute minimum of heat would be
deposited in the artery, since the typical response of
arterial wall to thermal injury includes proliferative
healing and restenosis. Theminimumpulse energy for a
pulsed laser system is determined by the penetration
depth of the light and by the need to form a steam
bubble on each shot; effectively, this creates a unique
threshold energy density for each laser type.
Medical lasers have been evaluated for theFollow-up 1 month Follow-up 6 months
46 51
3 6
1 3
0 4
) 42/42 (100%) 38/42 (90%)
– 38/51 (74%)
3 2
1 2
0 2
) 38/42 (90%) 32/42 (76%)
LACI Belgium 617treatment of the most complex peripheral disease
since the mid-1980s. Early clinical applications of laser
angioplasty in severe atherosclerotic stenoses and
occlusions utilized continuous-wave (CW), hot-tipped
lasers, such as the Argon or the Nd:YAG lasers. In
contrast to the pulsed 308 nm excimer laser, continu-
ous wave laser systems constantly convert light energy
into thermal energy which diffuses into and injures the
surrounding tissue. Total thermal energy is transferred
to the metal cap at the end of the probe resulting in
temperatures in excess of 450 8C. Also, after the first
laser shot, the catheter probe becomes covered by a
layer of carbonized blood. The problem is com-
pounded in Argon lasers that employ a wavelength
that is actively absorbed by hemoglobin. This layer of
carbonized blood absorbs the laser energy and
prevents direct laser tissue interaction. Tissue ablation
is achieved by a denaturation of the tissue followed by
carbonization and vaporization. CW lasers also failed
to ablate or penetrate calcified plaques. Despite a high
technical success rate, these early experiments with
thermal, continuous wave lasers resulted in significant
complications such as aneurysm formation, late
perforations and a high restenosis rate. As a result,
continuous wave laser systems have been abandoned
for arterial applications.
Pulsed XeCl excimer laser angioplasty of the leg
arteries has been practised commercially in Europe
since 1994. Unlike continuous wave lasers, the excimer
laser makes optimal use of absorption depth, pulse
width and average power. In terms of absorption
depth, the excimer laser is to be placed in the UVB
region of the spectrum near 300 nm, where theTable 6. LACI 2 patient and limb characteristics
145 Patients
Mean age 72G10 (45–91)
Men 53%
Duration of CLI (weeks) 25G37 (1–261)
Risk factors
Smoking 53%
Coronary artery disease 50%
Prior stroke 21%
Diabetes mellitus 66%
Hypertension 83%
Dyslipidemia 56%
Obesity 35%
155 Limbs
Rutherford category
4 29%
5 or 6 71%
Reasons for poor surgical candidacy
Absence of venous graft 32%
Poor/no distal vessel 68%
High surgical risk 46%
Only one reason 61%
Any two reasons 33%
All three reasons 6%absorption depth is shallow, owing to absorption by
cellular macromolecules. At 308 nm, where the XeCl
laser emits, the typical absorption depth is about
0.05 mm (50 mm) and each photon of 308 nm light
carries enough energy to break a single carbon–carbon
bond. XeCl laser catheters remove a layer of about
10 mm thick with each pulse. Initially, photochemical
bond breaking weakens cellular structures, and later
cells explode when their internal water turns into
steam. This leaves sub-cellular debris, and a shallow
crater under the catheter. The debris washes down-
stream without embolizing distal capillaries, and the
catheter tip advances into the crater. On the next laser
pulse, the process repeats, allowing the catheter tip to
nibble through the tissue, as each laser pulse removes
a thin layer of tissue at the bottom of the crater. As all
lasers convert the light energy absorbed by the tissue
immediately to heat, the thermal effect in the irra-
diated tissue has to be confined in order to use pulsed
lasers, such as the XeCl excimer laser successfully.
Therefore, the laser pulse must deliver its energy in a
time span much shorter than it takes for the heat to
diffuse away from the tip of the catheter. Once thermal
confinement is assured, tissue ablation can be
achieved by forcing the tissue to absorb enough
energy in one pulse to vaporize the most volatile
liquid in the cells-water. This is accomplished by
transmitting sufficient energy per pulse, through each
fiber in the catheter, to ensure that the water content of
the tissue in the thermal confinement zone under each
fiber vaporizes. When looking at the average power,
the threshold energy density for XeCl lasers is about
35 mJ of energy per square millimeter (mJ/mm2) of
optical fiber in the catheter tip. A typical 2 mm
diameter excimer laser catheter has about .71 mm2 of
fiber and delivers 25 mJ of energy per pulse at the
minimum fluence. Delivering significantly more
energy than this creates a more violent reaction in
the tissue (which can be advantageous in particularly
tough or calcified lesions) but deposits greater heat in
the process. In a nutshell, the 308 nm excimer laser
utilises flexible fiber optic catheters to deliver intense
bursts UV energy in short pulse durations. The
advantages of UVB light are its short penetration
depth of 50 mm and its ability to break molecular
bonds directly, by a photochemical, rather than
thermal, process similar to the widely used technique
of excimer laser photorefractive keratectomy. (LASIK).
With the knowledge that medical lasers have
matured and with the recent publications on excimer
laser assisted angioplasty, we looked into the most
recent data available. Previously, the LACI 2 study
enrolled, CLI patients with the same inclusion and
exclusion criteria as LACI Belgium.24 At 15 sites in theEur J Vasc Endovasc Surg Vol 29, June 2005
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155 critically ischemic limbs and 423 lesions. Patient
and limb characteristics were typical of patients with
systemic vascular disease, but with a higher incidence
of diabetes and non-healing ulcers (Rutherford cat-
egory 5–6) than in LACI Belgium. LACI 2 patients
presented with severe and diffuse vascular disease
typical of critical limb ischemia (Table 6). In the 423
lesions, 41%were in the superficial femoral artery, 15%
were in the popliteal artery and 41% were in
infrapopliteal arteries. Further, 70% of the patients
had a combination of stenoses and occlusions, making
treatment very complex. In 26 cases, where step-by-
step technique was used, procedure success ensued in
20 (77%), resulting in 6-month limb salvage in 21/23
(91%) of survivors. Serious adverse events in this
subset were not significantly different from the rest of
LACI 2 cases, indicating that step-by-step technique
adds little additional risk to this patient group while
substantially increasing the chances for success in total
occlusions. In-hospital serious adverse events were
infrequent in this very fragile patient group. There
were no deaths, perforations with surgical repair or
bypasses as a result of the procedure and no patient
had acute limb ischemia post intervention. Serious
adverse events during the 6-month enrolment period
included 10% mortality, almost exclusively from
cardiac causes. Major amputation was required in 11
cases, while four limbs received surgical intervention.
Endovascular reinterventions were performed in 24
cases, as could be expected given the complexity of the
disease. However, of surviving legs, 69% improved in
Rutherford category, 27% maintained the sameTable 7. LACI 2 results
Procedure results
Guidewire crossing success 92%
Laser treatment delivered 99%
Adjunctive balloon 96%
Stent placement 45%
Procedure success 85%
!50% residual stenosis at final
Straight-line flow established 89%
Mean hospital stay (days) 3
Adjudicated SAEs
In-hospital All follow-up Total
Death 0 15 15
Major amputation 2 9 11
Non-fatal MI or Stroke 0 2 2
Reintervention 1 23 24
Hematoma w/surgery 1 0 1
Acute limb ischemia 0 1 1
Perforation w/surgery 0 0 0
Bypass 0 3 3
Endarterectomy 0 1 1
48 (33%) of patients experienced at least 1 SAE
Eur J Vasc Endovasc Surg Vol 29, June 2005Rutherford category and only 4% declined. At 6
months, limb salvage was achieved in 93% of the
surviving legs. Overall the results of LACI 224 and
LACI Belgium show a remarkably similar record of
success in a similar patient population. This finding
supports the ability to translate an effective but
somewhat complex endovascular strategy from inter-
national centres of excellence to selected centres within
a national framework of healthcare standards
(Table 7).Conclusions
For patients with CLI, preserved mobility and quality
of life should be the main factors in deciding on leg
salvage attempts vis-a`-vis primary amputation. The 6-
month results of the LACI Belgium study confirm the
excellent limb salvage rates in the selected patient
population, seen previously in the LACI 2 study.24 It is
mandatory to emphasise that these patients were
screened and selected as poor surgical candidates and
presented with complex vascular disease that typically
disqualifies them from bypass surgery. By using a
single treatment strategy, and taking account of the
early excimer laser experience of all participating
centres, nearly all surviving patients retained their
limbs, with clinically significant improvement in
Rutherford category and a low incidence of
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